Western blot confirmed stable MUC1 expression in multiple pancreatic cancer cell lines (PANC-1, BxPC-3, MIA PaCa-2), providing a molecular rationale for MUC1-targeted immunotherapy. The gene discussed is MUC1; the disease is pancreatic neoplasm.